Cargando…

Loss-of-function lesions impact B-cell development and fitness but are insufficient to drive CLL in mouse models

Detalles Bibliográficos
Autores principales:	Hacken, Elisa ten, Yin, Shanye, Redd, Robert, Sánchez, María Hernández, Clement, Kendell, Hoffmann, Gabriela Brunsting, Regis, Fara F., Witten, Elizabeth, Li, Shuqiang, Neuberg, Donna, Pinello, Luca, Livak, Kenneth J., Wu, Catherine J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	The American Society of Hematology 2022
Materias:	Research Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10425678/ https://www.ncbi.nlm.nih.gov/pubmed/36477552 http://dx.doi.org/10.1182/bloodadvances.2022009135

Ejemplares similares

Generation of mouse models carrying B cell restricted single or multiplexed loss-of-function mutations through CRISPR-Cas9 gene editing
por: ten Hacken, Elisa, et al.
Publicado: (2023)

High throughput single-cell detection of multiplex CRISPR-edited gene modifications
por: ten Hacken, Elisa, et al.
Publicado: (2020)

Mutations driving CLL and their evolution in progression and relapse
por: Landau, Dan A., et al.
Publicado: (2015)

The Dohner fluorescence in situ hybridization prognostic classification of chronic lymphocytic leukaemia (CLL): the CLL Research Consortium experience
por: Van Dyke, Daniel L., et al.
Publicado: (2016)

AmpUMI: design and analysis of unique molecular identifiers for deep amplicon sequencing
por: Clement, Kendell, et al.
Publicado: (2018)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
por: Sitlinger, Andrea, et al.
Publicado: (2021)

CRISPR/Cas9-generated models uncover therapeutic vulnerabilities of del(11q) CLL cells to dual BCR and PARP inhibition
por: Quijada-Álamo, Miguel, et al.
Publicado: (2020)

Frontline Treatment of the Young, Fit Patient with CLL: A Canadian Perspective
por: Costello, Jacqueline, et al.
Publicado: (2021)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

A Code of Ethics for Gene Drive Research
por: Annas, George J., et al.
Publicado: (2021)

Identification of a structurally novel BTK mutation that drives ibrutinib resistance in CLL
por: Sharma, Shruti, et al.
Publicado: (2016)

Coevolving JAK2(V617F+)relapsed AML and donor T cells with PD-1 blockade after stem cell transplantation: an index case
por: Penter, Livius, et al.
Publicado: (2021)

CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

Do age, fitness, and concomitant medications influence management and outcomes of patients with CLL treated with ibrutinib?
por: Tedeschi, Alessandra, et al.
Publicado: (2021)

Leptomeningeal involvement in CLL
por: Chantepie, Sylvain P., et al.
Publicado: (2014)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Poster: CLL-033 Is COVID-19 Infection a Trigger for Progression of CLL?
por: Popov, Viola, et al.
Publicado: (2022)

CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

CLL-IPI applied in Binet A CLL: a nationwide cohort study
por: Rotbain, Emelie C., et al.
Publicado: (2022)

Poster: CLL-461 Humoral Response to COVID-19 Vaccine: A Challenge in CLL
por: Capasso, Antonella, et al.
Publicado: (2022)

An APOBEC3A-Cas9 base editor with minimized bystander and off-target activities
por: Gehrke, Jason M., et al.
Publicado: (2018)

Medical fitness to drive, emergency service vehicles and crash risk
por: Noonan, Donna, et al.
Publicado: (2023)

Significance of t (8: 14) in CLL?
por: Lakshmaiah, K. C., et al.
Publicado: (2010)

CLL kinetics in the tumor microenvironment
por: Sun, Clare, et al.
Publicado: (2017)

Tumor suppressors revival in CLL
por: Carrà, Giovanna, et al.
Publicado: (2017)

CLL und Covid-19
por: Behrend, Christian
Publicado: (2022)

Current Treatment Options in CLL
por: Bewarder, Moritz, et al.
Publicado: (2021)

PB1952: CLL IN AYA
por: Mohamed, Shehab, et al.
Publicado: (2023)

COVID-19 severity and mortality in patients with CLL: an update of the international ERIC and Campus CLL study
por: Chatzikonstantinou, Thomas, et al.
Publicado: (2021)

Generation of Functional CLL-Specific Cord Blood CTL Using CD40-Ligated CLL APC
por: Decker, William K., et al.
Publicado: (2012)

Double IGHV DNA gene rearrangements in CLL: influence of mixed-mutated and -unmutated rearrangements on outcomes in CLL
por: Heyman, B, et al.
Publicado: (2016)

The CLL International Prognostic Index predicts outcomes in monoclonal B-cell lymphocytosis and Rai 0 CLL
por: Parikh, Sameer A., et al.
Publicado: (2021)

Phase 1 TRANSCEND CLL 004 study of lisocabtagene maraleucel in patients with relapsed/refractory CLL or SLL
por: Siddiqi, Tanya, et al.
Publicado: (2022)

T cell activation is insufficient to drive SIV disease progression
por: Apetrei, Cristian, et al.
Publicado: (2023)

Ibrutinib Resistance Is Reduced by an Inhibitor of Fatty Acid Oxidation in Primary CLL Lymphocytes
por: Galicia-Vázquez, Gabriela, et al.
Publicado: (2018)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

Critical molecular pathways in CLL therapy
por: Ferrer, Gerardo, et al.
Publicado: (2018)

Reactivating nuclear PTEN to treat CLL
por: Bernardi, Rosa, et al.
Publicado: (2017)

Ibrutinib dose modifications in the management of CLL
por: Hardy-Abeloos, Camille, et al.
Publicado: (2020)

When CLL meets COVID-19
por: Montserrat, Emili
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_7dokh7352p00t4oaf9kajhl5ap